Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Definitions

• antioxidants used in foods are acids and phenolic compounds.
• acid antioxidants are ascorbic and citric acids
• phenolic antioxidant compounds include BHA, BHT, TBHQ, Tocopherols, Lecithin, THBP, Gum and Glycine.
• a lyophilized reagent composition may be used that comprises the aforementioned activator composition and particles.
• a metered volume of a sample to be measured such as whole blood
• a change in light transmission is monitored and an index of platelet activity calculated.
• a whole blood sample is combined in a cuvette or a unitized cartridge with the aforementioned lyophilized reagent.
• An apparatus may be employed for carrying out the assay.
• the apparatus can include a well for receiving the sample where the well contains the lyophilized reagent and other reagents for conducting the assay.
• the additional reagents may be various buffers and/or lyophilization stabilizers, and the like.
• GPIIb/llla receptors on the surface of platelets bind, complex or otherwise interact with the GPIIb/llla receptor ligands on the particles.
• Suitable GPIIb/llla ligands include fibrinogen, monoclonal antibody 10E5 (Coller, et al., J. Clin. Invest. 72:325 (1983)), monoclonal antibody c7E3 (The EPIC Investigators, N. E.
• the compound is coated on the particles, often by covalent attachment to the particles.
• covalent attachment can be accomplished by well-known techniques, commonly available in the literature. See, for example, "Immobilized Enzymes,” Ichiro Chibata, Halsted Press, New York (1978) and Cuatrecasas, J. Biol. Chem., 245:3059 (1970).
• the surface of the particle may be polyfunctional or be capable of being polyfunctionalized.
• a wide variety of functional groups are available or can be incorporated. Functional groups include carboxylic acids, aldehydes, amino groups, cyano groups, ethylene groups, hydroxyl groups, mercapto groups and the like.
• the pH for the medium can be in the range of about 2 to about 11 , preferably, about 4 to about 9.
• Various buffers may be used to achieve the desired pH and maintain the pH during the method.
• Illustrative buffers include HEPES, borate, phosphate, carbonate, Tris, barbital, and the like.
• the particular buffer employed is not critical to the method but one buffer may be preferred over others in certain circumstances. In some circumstances HEPES is preferred and is present at a concentration of about 0.05M to about 0.001 M but generally at a concentration of about 0.01 M.
• the sample After the sample has been combined with the reagents, it can be heated to a temperature above room temperature, but below that which would interfere with the assay, so as to insure that the temperature can be controlled without adversely affecting the assay result. Desirably, the temperature can be at least 25°, preferably in the range of 30-40 0 C, more preferably about 37°C.
• the reaction medium is usually gently agitated upon combining of the reagents with the sample and during the period of the reaction. Agitation is sufficient to achieve and maintain homogeneity in the assay samples.
• the total time of the readings from the zero time (time of mixing) may range from about 10 sec. to 10 min., more usually about 30 sec. to 8 min., and preferably about 30 sec. to 3 min.
• the data may be analyzed by any convenient means, particularly using an algorithm that can manipulate the data in relation to calibrators and/or controls.
• the above assays preferably may be conducted in a device, which allows the reactions in accordance with the present invention to occur and which measures the results thereof.
• the instrument can assess platelet function based upon the ability of activated platelets to bind fibrinogen. As activated platelets bind and agglutinate fibrinogen-coated particles, there is an increase in light transmittance.
• an instrument to measure the result of the assay is one that can measure agglutination.
• the instrument measures a change in optical signal due to agglutination.
• Suitable instruments include, by way of illustration and not limitation a kinetic spectrophotometer, Ultegra System ® instrument (commercially available from Accumetrics, San Diego, CA) and employed for rapid platelet function activity measurements on normal samples), and the like.
• an assay for platelet function activity is conducted on a whole blood sample from a patient undergoing treatment with aspirin.
• the sample is combined in a suitable container, e.g., reaction cuvette, with a reagent that includes particles coated with a compound that results in a specific agglutination of platelets, to form an assay medium.
• the compound is an antibody to a platelet receptor and GPIIb/llla receptor ligands.
• the particles have one or more infrared dyes incorporated therein.
• a buffer is provided and the pH is about 2 to about 11.
• the combination is subjected to agglutination conditions.
• the medium is irradiated with light in the infrared region using the Ultegra® System.
• the transmission of infrared light from the assay mixture is determined where the level of transmission is related to platelet function activity.
• an assay for platelet function activity is conducted on a whole blood sample from a patient undergoing treatment with aspirin.
• the sample is combined in a suitable container, e.g., reaction cuvette, with utilizing a reagent that includes particles coated with a compound that results in a specific agglutination of platelets, to form an assay medium.
• the compound is an antibody to a platelet receptor and GPIIb/llla receptor ligands.
• the particles of the particle reagent have one or more infrared dyes incorporated therein.
• the combination is subjected to agglutination conditions and incubated at a temperature of at least 25°. Th ⁇ medium is irradiated with light in the infrared region using the Ultegra® System. The transmission of infrared light from the assay mixture is determined where the level of transmission is related to platelet function activity.
• an assay for platelet function activity is conducted on a whole blood sample from a patient undergoing treatment with aspirin.
• the sample is combined in a suitable container, e.g., reaction cuvette, with utilizing a reagent that includes particles coated with a compound that results in a specific agglutination of platelets, to form an assay medium.
• the compound is an antibody to a platelet receptor and GPIIb/llla receptor ligands.
• the particles of the particle reagent have one or more infrared dyes incorporated therein.
• the combination is subjected to agglutination conditions and incubated at a temperature of at least 25°.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Organic Chemistry (AREA)
• Virology (AREA)
• Sustainable Development (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37215050

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (8)

Citations (3)

Family Cites Families (4)

• 2005
  • 2005-04-28 US US11/119,360 patent/US7205115B2/en not_active Expired - Fee Related
• 2006
  • 2006-04-14 JP JP2008508905A patent/JP5349957B2/ja not_active Expired - Fee Related
  • 2006-04-14 CA CA002604845A patent/CA2604845A1/en not_active Abandoned
  • 2006-04-14 CN CNA2006800228492A patent/CN101208603A/zh active Pending
  • 2006-04-14 KR KR1020077027636A patent/KR101350528B1/ko not_active Expired - Fee Related
  • 2006-04-14 EP EP10193726A patent/EP2341347A1/en not_active Withdrawn
  • 2006-04-14 EP EP06750226A patent/EP1877786B1/en not_active Not-in-force
  • 2006-04-14 AU AU2006240257A patent/AU2006240257B2/en not_active Ceased
  • 2006-04-14 AT AT06750226T patent/ATE524734T1/de not_active IP Right Cessation
  • 2006-04-14 WO PCT/US2006/014136 patent/WO2006115844A1/en not_active Ceased
• 2012
  • 2012-06-26 JP JP2012142879A patent/JP5810039B2/ja active Active

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events